Typical follow-up schedules include an initial follow-up at 4 weeks after starting to assess initial tolerance and response, then follow-up at each dose increase (when moving from 0.25mg to 0.5mg to 1mg), and quarterly appointments once youre on a stable maintenance dose
These include: G-protein coupled receptor (GPCR) family C group 6 subtype A (GPRC6A), Taste Rs (amino acids), G-protein coupled receptor 93 (GPR93) (peptones), free-fatty acid receptor 2 (FFAR2), free-fatty acid receptor 3 (FFAR3), short-chain fatty acid (SCFA), free-fatty acid receptor 1 (FFAR1), free-fatty acid receptor 4 (FFAR4), long-chain fatty acid (LCFA) and G-protein coupled receptor 119 (GPR119) [oleoylethanolamide (oea)] are some of the macronutrient-sensing receptors present on enteroendocrine cells (Spreckley and Murphy, 2015)
Basically, GLP-1 is here to tell you that you can stop eating, and this is very important, of course
It still lacks product-specific human BPC data
Patients should be reassured that whilst bubble removal is good practice for ensuring dose accuracy, the presence of tiny bubbles does not constitute a medical emergency or reason to skip a dose
